FT-104

Last updated

FT-104
RE104.svg
Clinical data
Other namesRE-104; RE104; 4-Glutaryloxy-N,N-diisopropyltryptamine; 4-Hydroxy-N,N-diisopropyltryptamine O-glutarate; O-Glutaryl-4-hydroxy-N,N-diisopropyltryptamine; 4-HO-DiPT glutarate; O-Glutaryl-4-HO-DiPT
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Duration of action 3.7 hours [1]
Identifiers
  • 1-[3-[2-[Bis(1-methylethyl)amino]ethyl]-1H-indol-4-yl] pentanedioate
CAS Number
PubChem CID
UNII
Chemical and physical data
Formula C21H30N2O
Molar mass 326.484 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C
  • InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25)
  • Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N

FT-104, also known as RE-104 and as 4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPT O-glutarate), is a psychedelic tryptamine derivative which is a prodrug ester of the well known designer drug 4-HO-DiPT. [2] It is one of a number of related derivatives developed for potential medical applications, and is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression. [3] [4] [5] [6]

Contents

It is being developed by the pharmaceutical company Reunion Neuroscience. [7]  As of 2024, FT-104 is entering Phase II clinical trials for post-partum depression. [8]

Pharmacology

FT-104 is a prodrug that is converted into the psychedelic tryptamine 4-HO-DiPT upon administration. [2] [9]  4-OH-DiPT then acts as an agonist on the serotonin 2A receptor which leads to an antidepressant effect. [7] Its duration in humans has been found to be 3.7 hours. [1]

Research

A clinical study of FT-104 for treatment of postpartum depression (PPD) has been published. [1]

See also

References

  1. 1 2 3 Pollack M, Hocevar-Trnka J, Bryson N, Taylor B, Johnson M, Alexander R (December 2024). "ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P697. RE104: A Novel, Shorter-Acting Psychedelic for Post Partum Depression". Neuropsychopharmacology. 49 (Suppl 1): 418–594 (469–470). doi: 10.1038/s41386-024-02013-y . PMID   39643635.
  2. 1 2 Bryson N, Alexander R, Asnis-Alibozek A, Ehlers MD (June 2024). "RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine". ACS Chemical Neuroscience. 15 (12): 2386–2395. doi:10.1021/acschemneuro.4c00058. PMC   11191588 . PMID   38758589.
  3. ↑ Hallifax J (11 August 2022). "An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104".
  4. ↑ WO 2022/000091,Bryson N,"Tryptamine prodrugs",published 6 January 2022, assigned to Field Trip Psychedelics Inc.
  5. ↑ US 2022/0024956,Slassi A, Araujo J,"Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders.",published 27 January 2022, assigned to Mindset Pharma Inc.
  6. ↑ WO 2022/246572,Slassi A, Araujo J, Higgin GH, Gabriele J,"Hallucinogen-Fatty Acid Combination",published 1 December 2022, assigned to Mindset Pharma Inc.
  7. 1 2 Braner S (May 8, 2024). "Reunion Neuroscience raises $103 million for a psychedelic to treat depression". Chemical & Engineering News .
  8. ↑ Alexander R, Hocevar-Trnka J (June 26, 2024). "RE104: A Novel, Fast-Acting Psychedelic for Postpartum Depression". psychiatrictimes.com.
  9. ↑ "Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders". GlobalNewswire. May 20, 2024 – via Yahoo!Finance.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.